Jubilant Generics Roorkee facility determined as official action indicated
Noida: Jubilant Pharmova Limited's wholly owned subsidiary Jubilant Pharma Limited, today announced that its subsidiary Jubilant Generics Limited (JGL) has received a communication from the US Food and Drug Administration (USFDA) through which the latter intimated that pursuant to its July-Aug 2022 audit of JGL's Solid Dosage Manufacturing facility at Roorkee it has determined inspection classification of the facility as "official action indicated".
The Company currently supplies one product to US market that contributes low- single digit revenue to Jubilant Pharmova revenues.
"The Company has been continuously cooperating with the USFDA and will undertake all necessary steps to resolve regulatory status at the Roorkee facility," Jubilant Pharmova stated.
Read also: USFDA issues 6 observations for Jubilant Pharmova Roorkee facility
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.